Abstract

PurposeSolitary eyelid juvenile xanthogranuloma (JXG) is extremely rare, and there is limited literature on its clinical features and treatment outcomes. Here, we present a case series and comprehensive review of the literature on patients with isolated eyelid JXG.MethodsWe systematically extracted data from our institution’s records of isolated eyelid JXG cases and conducted a search for additional cases from the literature utilising the PubMed, Wanfang, and Chinese National Knowledge Infrastructure (CNKI) databases. Patients with JXG were analysed with respect to age, sex, clinical presentation, therapy, and outcome. Group comparisons were performed.ResultsThirty-two patients (including 13 at our institution and 19 from prior publications) were identified. The median age at first presentation was higher in current patients than in the patients from the published cases (median 9 years, range 1.2 to 47.0 years; median 2 years, range 0.5 months to 46.0 years, respectively, P = 0.014). Of the patients who had known characteristics, no significant differences were observed between the two groups in terms of sex, affected eye, eyelid site, type of cutaneous involvement, or duration of symptoms (each P > 0.05). Seventeen (54.8%) patients were male. The most common lesion location was the upper eyelid (n = 10, 62.5%). Twenty-four (75.0%) cutaneous lesions had full-thickness skin involvement; 8 (25.0%) subcutaneous masses had a chalazion-like appearance. Histologically, the JXG masses were characterised by Touton giant cells with inflammatory cells. Additionally, there was no significant difference in treatment modalities between the two groups (P = 0.072), and 24 (75.0%) patients underwent surgical excision. The overall recurrence-free survival was 3.6 to 52.8 (median 27.0) months in the current patients. For published cases with available follow-up information, there was no recurrence in 10 cases and improvement in 1 case, with a median follow-up of 9.5 months.ConclusionSolitary eyelid JXG is a rare clinical entity and should be included in the differential diagnosis of eyelid mass lesions in patients of all age groups. Surgical excision is often selected for efficient treatment and to obtain an excisional biopsy.

Highlights

  • Juvenile xanthogranuloma (JXG) is the most common form of non-Langerhans cell histiocytosis, and it usually presents in infancy and early childhood

  • During the period between June 2016 and July 2020, 17 patients with JXG were sampled at our institution; we identified 13 patients diagnosed with solitary JXG of the eyelid

  • In addition to the aforementioned case series, we identified 19 additional patients with solitary eyelid JXG in 18 prior publications (Table S1) for a total of 32 patients

Read more

Summary

Introduction

Juvenile xanthogranuloma (JXG) is the most common form of non-Langerhans cell histiocytosis, and it usually presents in infancy and early childhood. Up to 90% of the JXG cases are cutaneous lesions occurring in the head and neck, which are the most common sites that are involved [1,2,3,4]. Adults may be affected [5], the lesions mostly occur spontaneously within the first year of life as cutaneous nodules that can be yellow or a range of other colours [6], and they can regress spontaneously [7]. JXG has been reported to represent 0.5% of all paediatric tumours [8]. The patient’s general health is not impaired, and in the absence of associated conditions, the prognosis is excellent.

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.